Pneuma Respiratory has announced a licensing agreement with Nanjing Leads Biolabs subsidiary Leads Biolabs, Inc. for rights to develop Leads monoclonal antibodies and fusion protein molecules for delivery using Pneuma’s digital soft mist inhaler. Pneuma said that it plans to develop inhaled immuno-oncology drugs.
Pneuma Respiratory CEO and Co-Founder Eric Hunter commented, “We are pleased to enter into a license agreement for Leads Biolabs monoclonal antibody portfolio. We look forward to working with their team to conduct studies that may lead to positive change in the future treatment of non-small cell lung cancer.”
Leads Biolabs Chairman and CEO Xiaoqiang Kang said, “We are very excited to have this license agreement with Pneuma Respiratory. The commitment by a leader in digital pulmonary delivery of drugs is an endorsement of the value of our portfolio. We believe that Pneuma’s digital inhaler technology combined with our antibody drugs will create very exciting new opportunities for both companies. We look forward to working with Pneuma to move our candidates into the clinic as quickly as possible.”
Pneuma Respiratory introduced its digital soft mist inhaler in 2017, primarily touting its potential for COPD therapies but noting that the platform had the capability to deliver large molecule drugs. In August 2018, the company announced that Chinese rights to its respiratory products had been acquired by Haisco Pharmaceutical Group.
Read the Pneuma Respiratory press release.
